Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.Diabetes care · 2018
   Trial
2. Metabolic reprogramming by endothelial ANGPTL4 depletion protects against diabetic kidney disease.bioRxiv : the preprint server for biology · 2025
   Article
3. ANGPTL4-the Link Binding Lipid Metabolism and Inflammation.Current medicinal chemistry · 2025
   Review
4. Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies.Journal of clinical medicine · 2024
   Article
5. Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases.Frontiers in immunology · 2020
   Review
6. ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in participants with obesity.Obesity science & practice · 2019
   Article
7. RareFrontiers in cell and developmental biology · 2019
   Article
8. Nutrition & metabolism · 2018
   Article
9. Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing.PloS one · 2017
   Article

Corrections and comments

• Comment on
  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.2016
• Comment on
  Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.2016
• Comment on
  Variants in ANGPTL4 and the Risk of Coronary Artery Disease.2016
• Comment on
  Variants in ANGPTL4 and the Risk of Coronary Artery Disease.2016
• Comment on
  Variants in ANGPTL4 and the Risk of Coronary Artery Disease.2016
• Comment on
  Variants in ANGPTL4 and the Risk of Coronary Artery Disease.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.